Gut bacterial tyrosine decarboxylase as a predictive biomarker to identify Parkinson’s disease patients with motor fluctuations requiring frequent levodopa administration
Objective: To Investigate the clinical relevance of tyrosine decarboxylating (TDC)-bacteria in patients with Parkinson’s Disease (PD). Background: Recently, we have shown that TDC-gut bacteria that…Patterns of Cortical Thinning in Patients with Parkinson’s Disease
Objective: To investigate patterns of cortical thickness that are associated with disease severity and response to levodopa. Background: Cortex affection is a neuropathological correlate of…The GlyT1 inhibitor bitopertin reduces in the 6-OHDA-lesioned rat model of Parkinson’s disease
Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with bitopertin on dyskinesia in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s disease (PD).…The modification of iron accumulation in nigrosome by levodopa treatment in early Parkinson’s disease
Objective: The study was to investigate the alteration of iron accumulation in nigrosome for the early treatment of dopamine loss in PD. Background: Iron accumulation…Levodopa improves tremor symptom by reducing the connectivity between the thalamic subregions and postcentral gyrus in patients with Parkinson’s disease
Objective: To explore the mechanism by which levodopa modulates the functional connectivity of the subregions of the thalamus and which subregional connectivity changes are associated…Researches on the correlation between wearable device data and UPDRS scores in patients with Parkinson’s disease
Objective: To collect spatiotemporal parameter information of motor symptoms in patients with Parkinson's disease (PD) using wearable device, and analyze its correlation with the Unified…Pharmacokinetics of Levodopa in patients with Parkinson’s disease: Efforts toward a predictive model
Objective: Our aim was to explore correlations between the pharmacokinetics of levodopa (LD) and clinical manifestation in patients with Parkinson’s disease (PD). Our goal was…PF-QII Analysis of Deep Brain Stimulation versus Levodopa-carbidopa Intestinal Gel: Real-world Differences in Patient Characteristics and Quality of Life Outcomes
Objective: To evaluate differences in demographics, disease characteristics, quality of life (QOL), and caregiver burden (CB) between deep brain stimulation (DBS) and levodopa-carbidopa intestinal gel…Temporal properties of resting-state functional MRI are associated with ON/OFF levodopa MDS-UPDRS III scores in patients with Parkinson’s disease
Objective: To explore the relationship between temporal resting-state functional magnetic resonance imaging (fMRI) properties and ON/OFF Levodopa motor performance scores in patients with Parkinson's disease…Daily Time-Course of Efficacy of Continuous Subcutaneous Infusion of Foslevodopa/foscarbidopa in Advanced Parkinson’s Disease Patients from a Phase 1b Study
Objective: Characterize and compare the time-course of Parkinson’s disease (PD) symptoms following 24h/day continuous subcutaneous infusion (CSCI) of foslevodopa/foscarbidopa and oral levodopa/carbidopa (LD/CD). Background: As…
- « Previous Page
- 1
- …
- 25
- 26
- 27
- 28
- 29
- …
- 62
- Next Page »